There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > IL-5


Brief Information

Target Synonym:T-cell replacing factor,IL5,Interleukin 5,Eosinophil Differentiation Factor,Colony-Stimulating Factor, Eosinophil,B-Cell Differentiation Factor I,Interleukin-5,IL-5,TRF,Interleukin 5 (Colony-Stimulating Factor, Eosinophil),B Cell Differentiation Factor I,
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:4
Lastest Research Phase:Approved

Product ListCompare or Buy

Part of Bioactivity data


Loaded Human IL-5, His Tag (Cat. No. IL5-H52H3) on NTA Biosensor, can bind Human IL-5 R alpha, Fc Tag (Cat. No. ILA-H5259) with an affinity constant of 4.63 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Mouse IL-5, His TagMouse IL-5, His Tag (Cat. No. IL5-M52H3) ELISA bioactivity

Immobilized Mouse IL-5, His Tag (Cat. No. IL5-M52H3) at 5 μg/mL (100 μL/well) can bind Human IL-5 R alpha, Fc Tag (Cat. No. ILA-H5259) with a linear range of 5-39 ng/mL (QC tested).

Synonym Name



Interleukin 5 (IL5) is an interleukin produced by type-2 T helper cells and mast cells. IL-5 is a 115-amino acid (in human, 133 in the mouse) -long TH2 cytokine that is part of the hematopoietic family. Unlike other members of this cytokine family (namely interleukin 3 and GM-CSF), this glycoprotein in its active form is a homodimer. Interleukin-5 has long been associated with the cause of several allergic diseases including allergic rhinitis and asthma, wherein a large increase in the number of circulating, airway tissue, and induced sputum eosinophils have been observed. Given the high concordance of eosinophils and, in particular, allergic asthma pathology, it has been widely speculated that eosinophils have an important role in the pathology of this disease. Drugs that target IL-5 are mepolizumab and reslizumab.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Reslizumab TRFK-5; CDP-835; SCH-5570; CEP-38072; CTx-55700; SCH-55700 Approved Teva Pharmaceutical Industries Ltd Cinqair, Cinquil, Cinqaero EU Asthma Teva Bv 2016-03-23 Pulmonary Eosinophilia; Eosinophilic Esophagitis; Asthma Details
Mepolizumab SB-240563; 240563 Approved Glaxosmithkline Plc Nucala, Bosatria United States Hypereosinophilic Syndrome Glaxosmithkline Llc 2015-11-04 Hypereosinophilic Syndrome; Granulomatosis with Polyangiitis; Churg-Strauss Syndrome; Nasal Polyps; Eosinophilic Esophagitis; Asthma; Eosinophilic Granuloma; Sinusitis; Pulmonary Disease, Chronic Obstructive; Dermatitis, Atopic Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
long-acting anti-IL-5 mAb (GSK) Phase 1 Clinical Glaxosmithkline Plc Asthma Details
GSK-3511294 GSK-3511294; GSK-294; GSK3511294; GSK294 Phase 3 Clinical Glaxosmithkline Plc Asthma Details
Orismilast LP-0058; LEO-32731 Phase 2 Clinical Leo Pharma Inc Drug-Related Side Effects and Adverse Reactions; Psoriasis; Dermatitis, Atopic Details
Recombinant anti-IL-5 humanized monoclonal antibody (Shanghai CP Guojian) 610 Phase 1 Clinical Shanghai Cp Guojian Pharmaceutical Co Ltd Autoimmune Diseases; Asthma Details
SHR-1703 SHR-1703 Phase 1 Clinical Suzhou Suncadia Biopharmaceuticals Co Ltd, Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd Asthma Details

This web search service is supported by Google Inc.